Vaccines in oncology: Background and clinical potential

British Journal of Radiology

Volumn 74, Issue 887, 2001, Pages 991-1002

  Armstrong, A C ^a   Hawkins, R E ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; CORYNEBACTERIUM PARVUM VACCINE; CYCLOPHOSPHAMIDE; DNA VACCINE; EPITOPE; MELANOMA VACCINE; ONCOFETAL ANTIGEN; PEPTIDE DERIVATIVE; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE ANTIGEN; TISSUE ANTIGEN; TUMOR ANTIGEN; TUMOR CELL VACCINE; VACCINIA VACCINE; VIRUS T ANTIGEN; VIRUS VACCINE;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNITY; CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SCREENING; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; IMMUNE RESPONSE; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; SEPTIC SHOCK; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0035198921     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr.74.887.740991     Document Type: Review

References (82)

1. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host
2. Immunity to methylcholanthrene-induced sarcomas
3. Myeloma proteins as tumor-specific transplantation antigens
4. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
5. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
6. Immunology: The ins and outs of antigen processing and presentation
7. Tumour antigens recognized by T lymphocytes
8. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo
9. Costimulation of T lymphocytes: The role of CD28, CTLA-4 and B7/BBI in interleukin-2 production and immunotherapy
10. Tolerance, danger and the extended family
11. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
12. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens
13. Study of antibodies against human melanoma produced by somatic cell hybrids
14. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
15. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells
16. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
17. Human neoplasms elicit multiple specific immune response in the autologous host
18. Carcino-embryonic antigen functions as an accessory adhesion molecule mediating colon epithelial cell-collagen interactions
19. Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors
20. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients
21. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
22. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
23. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
24. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
25. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer
26. Oncogenic proteins as tumor antigens
27. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group
28. Role of E6 and E7 oncoproteins in HPV-induced anogenital malignancies
29. Idiotypic DNA vaccines against B-cell lymphoma
30. Adoptive immunotherapy of newly induced murine sarcomas
31. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
32. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
33. Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy
34. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
35. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
36. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
37. Experimental and clinical studies of cytokine gene-modified tumor cells
38. Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials
39. Tumor-induced immunosuppression: A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine
40. Increased interleukin-10 serum levels in patients with solid tumours
41. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
42. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymomabearing mice
43. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
44. Spontaneous regression of subcutaneous metastasis of cutaneous melanoma
45. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
46. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
47. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
48. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor
49. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics
50. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor
51. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long term results of a clinical trial
52. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
53. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
54. Genetic immunization is a simple method for eliciting an immune response
55. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines
56. DNA immunization induces protective immunity against B-cell lymphoma
57. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
58. A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027
59. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
60. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
61. Isolation and characterization of dendritic cells from mouse heart and kidney
62. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells
63. Identification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alpha
64. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha
65. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells
66. Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells
67. High levels of a major histocompatibility complex II - Self peptide complex on dendritic cells from the T-cell areas of lymph nodes
68. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
69. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immunological responses in 26 patients
70. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
71. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
72. A comparison of gene transfer methods in human dendritic cells
73. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity
74. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
75. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
76. Idiotype-encoding recombinant adenovirus provide protective immunity against murine B-cell lymphomas
77. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283
78. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
79. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
80. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
81. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
82. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity